#1 Clinical Trials Search in Europe

Phenprocoumon

This article summarizes several clinical trials investigating the use of phenprocoumon, an oral anticoagulant medication, in various patient populations. The studies compare phenprocoumon to newer anticoagulants and explore its efficacy and safety for preventing blood clots in conditions like atrial fibrillation and in patients with mechanical heart valves or left ventricular assist devices.

Table of Contents

What is Phenprocoumon?

Phenprocoumon is an oral anticoagulant medication, also known by the brand names Marcoumar or Marcumar[1]. It belongs to a class of drugs called vitamin K antagonists, which are used to prevent blood clots from forming or growing larger[2]. Phenprocoumon is similar to another more commonly known anticoagulant called warfarin[3].

Conditions Treated with Phenprocoumon

Phenprocoumon is prescribed to treat and prevent various conditions related to blood clotting. These include:

  • Atrial Fibrillation: An irregular heart rhythm that increases the risk of stroke[1]
  • Pulmonary Embolism: A blood clot in the lungs[4]
  • Deep Vein Thrombosis: Blood clots in the deep veins, usually in the legs
  • Mechanical Heart Valve Recipients: Patients who have received artificial heart valves[2]
  • Left Ventricular Assist Device (LVAD) Patients: Those with a mechanical pump to support heart function[3]

How Phenprocoumon Works

Phenprocoumon works by interfering with the body’s vitamin K-dependent clotting factors. It reduces the blood’s ability to clot by blocking the action of vitamin K, which is necessary for the formation of certain clotting factors in the liver. This helps prevent harmful blood clots from forming or growing larger[2].

Dosage and Administration

The dosage of phenprocoumon is highly individualized and requires careful monitoring. It is typically taken orally once daily, with the dose adjusted based on blood test results. The goal is to achieve a specific range of blood thinning, measured by a test called the International Normalized Ratio (INR)[2].

For most conditions, the target INR range is between 2.0 and 3.0. However, for some patients with mechanical heart valves, a higher range of 2.5 to 3.5 may be recommended[2].

Monitoring During Treatment

Regular blood tests are crucial when taking phenprocoumon. These tests measure your INR and help your doctor adjust your dose to maintain the right level of anticoagulation. The frequency of these tests may vary, but they are typically done weekly when starting treatment and then less frequently once your INR is stable[2].

Potential Side Effects

The main risk associated with phenprocoumon is bleeding. This can range from minor bleeding (such as nosebleeds or easy bruising) to more serious bleeding events. Major bleeding complications can include:

  • Internal bleeding
  • Bleeding that requires hospitalization
  • Bleeding that necessitates blood transfusions[3]

It’s important to report any signs of unusual bleeding to your healthcare provider immediately.

Comparisons with Other Anticoagulants

Several clinical trials have compared phenprocoumon to newer anticoagulants:

  • Dabigatran: Studies have looked at how dabigatran compares to phenprocoumon in treating atrial fibrillation and resolving blood clots in the heart[5].
  • Rivaroxaban: Research has investigated whether rivaroxaban might have different effects on heart calcification compared to phenprocoumon[4].
  • Apixaban: Trials have examined the safety of apixaban versus phenprocoumon in patients with kidney disease who are on dialysis[1].

These newer drugs may offer some advantages, such as not requiring regular INR monitoring, but they also have their own risks and benefits that should be discussed with your doctor.

Special Considerations

There are some important things to keep in mind when taking phenprocoumon:

  • Diet: Vitamin K in foods can affect how phenprocoumon works. It’s important to maintain a consistent diet and avoid sudden changes in vitamin K intake.
  • Other medications: Many drugs can interact with phenprocoumon, either increasing or decreasing its effect. Always inform your healthcare providers about all medications you’re taking.
  • Surgery and dental procedures: You may need to stop taking phenprocoumon temporarily before certain procedures to reduce the risk of bleeding.
  • Pregnancy: Phenprocoumon can cause birth defects and should not be used during pregnancy[6].

Remember, while this information provides a general overview, your treatment with phenprocoumon should always be managed and monitored by a healthcare professional. They can provide personalized advice based on your specific medical condition and needs.

Study Focus Comparison Drug(s) Patient Population Key Outcomes Measured
Very low dose oral anticoagulation Phenprocoumon at different INR targets Mechanical heart valve recipients Thromboembolic events, bleeding events, survival rates
Appropriate initial dosing Phenprocoumon dosing algorithms Various indications for anticoagulation Rate of patients achieving therapeutic INR, complications
Left atrial thrombus resolution Dabigatran vs Phenprocoumon Atrial fibrillation with left atrial thrombus Thrombus resolution, cerebral embolism
Effect on platelet function Dabigatran vs Phenprocoumon Atrial fibrillation patients ADP-induced platelet aggregation
Anticoagulation in kidney disease Apixaban vs Phenprocoumon Atrial fibrillation with end-stage kidney disease Bleeding events, thromboembolic events
Use with left ventricular assist devices Dabigatran vs Phenprocoumon Patients with LVADs Thromboembolic complications, bleeding events

FAQ

  • What is phenprocoumon used for? Phenprocoumon is an oral anticoagulant medication used to prevent blood clots in conditions like atrial fibrillation, mechanical heart valves, and left ventricular assist devices.
  • How does phenprocoumon compare to newer anticoagulants? Several trials compared phenprocoumon to newer anticoagulants like dabigatran and apixaban. Results varied, but some studies found the newer drugs may offer benefits in certain patient groups.
  • What are some potential side effects of phenprocoumon? The main side effect of concern with phenprocoumon is bleeding. The trials monitored for major and minor bleeding events as a key safety outcome.
  • How is the dosing of phenprocoumon determined? Phenprocoumon dosing is typically adjusted to achieve a target INR (International Normalized Ratio) range, usually between 2.0-3.0. Regular INR monitoring is required.
  • Can phenprocoumon be used in patients with kidney disease? One trial specifically looked at using phenprocoumon versus apixaban in patients with end-stage kidney disease on hemodialysis. Kidney function is an important consideration for anticoagulant choice and dosing.

Ongoing Clinical Trials on Phenprocoumon

  • Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Edoxaban and Drug Combination for Patients with Atrial Fibrillation Needing Anticoagulation After Cardiac Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany The Netherlands

  • Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Germany Italy The Netherlands Spain

  • Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria

Glossary

  • Phenprocoumon: An oral anticoagulant medication that works by inhibiting vitamin K-dependent clotting factors. It requires regular monitoring and dose adjustments based on INR values.
  • INR (International Normalized Ratio): A standardized measurement of blood clotting time used to determine the effectiveness of anticoagulant medications like phenprocoumon.
  • Atrial Fibrillation: An irregular and often rapid heart rhythm that can increase the risk of blood clots, stroke, and other complications.
  • Left Ventricular Assist Device (LVAD): A mechanical pump implanted to help a weakened heart pump blood to the rest of the body.
  • Mechanical Heart Valve: An artificial heart valve implanted to replace a damaged or diseased natural heart valve.
  • Dabigatran: A newer oral anticoagulant that directly inhibits thrombin, not requiring regular INR monitoring.
  • Apixaban: A newer oral anticoagulant that inhibits factor Xa in the blood clotting process.
  • Thromboembolism: The blockage of a blood vessel by a blood clot that has traveled from elsewhere in the body.
  • Bleeding Events: Complications related to excessive bleeding, which can be a side effect of anticoagulant medications.
  • End-Stage Kidney Disease: Advanced kidney failure requiring dialysis or kidney transplantation.

References

  1. https://clinicaltrials.gov/study/NCT02933697
  2. https://clinicaltrials.gov/study/NCT00528671
  3. https://clinicaltrials.gov/study/NCT02872649
  4. https://clinicaltrials.gov/study/NCT02066662
  5. https://clinicaltrials.gov/study/NCT02256683
  6. https://clinicaltrials.gov/study/NCT01849666